⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378443 | 0.67 | — | — | |
| SCHEMBL485471 | 0.62 | — | — | |
| SCHEMBL855749 | 0.61 | — | — | |
| SCHEMBL30055270 | 0.61 | ALDH1A1 (0.44) | — | |
| SCHEMBL857672 | 0.61 | — | — | |
| SCHEMBL17265808 | 0.59 | ALDH1A1 (0.52) | — | |
| SCHEMBL5170029 | 0.56 | ALDH1A1 (0.59) | — | |
| SCHEMBL3934678 | 0.56 | — | — | |
| SCHEMBL858425 | 0.56 | — | — | |
| SCHEMBL128416 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3651768-B1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | UNIV TEXAS (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20210047311-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10800769-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3651768-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | Board of Regents, The University of Texas System (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200102296-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | SHANGPHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-10392376-B2 | Heterocyclic inhibitors of ATR kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-08-27 | — | — | US | disclosed |
| WO-2019014618-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190016713-A1 | HETEROCYCLIC INHIBITORS OF ATR KINASE | ARTIOS PHARMA LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| US-20100029643-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2137530-A2 | ANTAGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF | Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008056150-A1 | HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070276143-A1 | Method for producing optically active compound | YAMANO TORU | 2007-11-29 | — | — | US | disclosed |
| EP-1489070-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-08-29 | — | — | EP | disclosed |
| US-7247732-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060229457-A1 | Method for producing optically active compound | YAMANO TORU | 2006-10-12 | — | — | US | disclosed |
| US-7084278-B2 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050107433-A1 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1489070-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |